Provided by Tiger Trade Technology Pte. Ltd.

AIM ImmunoTech Inc.

0.1877
+0.01277.26%
Post-market: 0.1859-0.0018-0.96%18:18 EDT
Volume:832.25K
Turnover:149.92K
Market Cap:5.71M
PE:-0.05
High:0.1887
Open:0.1785
Low:0.1750
Close:0.1750
52wk High:2.88
52wk Low:0.1659
Shares:30.44M
Float Shares:28.51M
Volume Ratio:0.54
T/O Rate:2.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.9303
EPS(LYR):-30.8884
ROE:-2382.30%
ROA:-82.58%
PB:0.74
PE(LYR):-0.01

Loading ...

AIM ImmunoTech Says Phase 2 Duripanc Pancreatic Cancer Trial Advances Toward Q1 2027 Topline Data

Reuters
·
Yesterday

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as Duripanc Advances Toward Topline Data

THOMSON REUTERS
·
Yesterday

AIM ImmunoTech Expects Q1 2027 Topline Data from Phase 2 Duripanc Trial of Ampligen Plus Durvalumab in Metastatic Pancreatic Cancer

Reuters
·
Sep 30

AIM ImmunoTech Targets Q1 2027 Topline Data for Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca’s Imfinzi in Pancreatic Cancer

Reuters
·
Sep 22

AIM ImmunoTech CEO Thomas K Equels Acquires Common Shares Worth $4,992

Reuters
·
Sep 18

AIM ImmunoTech CEO Thomas K. Equels Acquires $4,862 Common Shares

Reuters
·
Sep 16

AIM ImmunoTech Issues 1,921,441 Shares in $450,000 Debt Exchange with Streeterville Capital

Reuters
·
Sep 11

AIM ImmunoTech Advances Phase 2 Duripanc Trial of Ampligen Plus AstraZeneca’s Imfinzi in Pancreatic Cancer

Reuters
·
Sep 09

AIM ImmunoTech Issues 5,065,840 Shares in Unregistered Note Exchange with Streeterville Capital

Reuters
·
Sep 05

AIM ImmunoTech Expands Ampligen Long COVID Patent Protection Across Europe, UK Through 2041

Reuters
·
Sep 02

AIM ImmunoTech Wins U.S. Patent Covering Ampligen-Keytruda Combo Cancer Therapy Through 2039

Reuters
·
Aug 31

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology Ip Protection for Ampligen Through 2039

THOMSON REUTERS
·
Aug 31

Morgans Sticks to Their Hold Rating for Ai-Media Technologies Limited (AIM)

TIPRANKS
·
Aug 28

Boku Tightens Free Float With Latest Share Buyback on AIM

TIPRANKS
·
Aug 27

Windar Photonics Directors Deepen Commitment in AIM Fundraise

TIPRANKS
·
Aug 27

Hargreave Hale AIM VCT Tightens Share Base with Buyback and Cancellation

TIPRANKS
·
Aug 26

PetroTal Non‑Executive Director Boosts Stake With AIM Share Purchase

TIPRANKS
·
Aug 26

Oxford BioDynamics Wins Shareholder Backing for Massive AIM Placing

TIPRANKS
·
Aug 26

Windar Photonics launches £4m equity raise amid accounting probe and AIM suspension

TIPRANKS
·
Aug 24

Trellus Health Appoints Administrators as AIM Delisting Looms

TIPRANKS
·
Aug 24